JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Glooko mHealth Advantage Study

  NCT02974816

  Condition:   Diabetes Mellitus, Type 2
  Intervention:   Device: Glooko's mobile application
  Sponsor:   Glooko
  Recruiting
• Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474

  Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Interventions:   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab;   Drug: Pemetrexed;   Drug: Pemetrexed Disodium;   Biological: Ramucirumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

  NCT03793179

  Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
  Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

  NCT03793166

  Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Malignant Neoplasm in the Viscera;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8
  Interventions:   Drug: Cabozantinib;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

  NCT03723928

  Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8;   Elevated CA15-3 or CEA or CA27-29
  Interventions:   Other: Usual care disease monitoring;   Other: Serum Tumor Marker directed disease monitoring;   Other: Quality-of-Life Assessment;   Other: Anxiety Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia

  NCT03701282

  Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
  Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Drug: Venetoclax
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery

  NCT03698019

  Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
  Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia

  NCT03654768

  Condition:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Drug: Ruxolitinib Phosphate
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

  NCT03578081

  Condition:   Malignant Neoplasm
  Interventions:   Drug: Palonosetron Hydrochloride;   Drug: Ondansetron Hydrochloride;   Drug: Dexamethasone;   Drug: Fosaprepitant Dimeglumine;   Drug: Olanzapine;   Other: Placebo
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

  NCT03499808

  Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
  Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

  NCT03414970

  Conditions:   Ductal Breast Carcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma;   Medullary Breast Carcinoma;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Tubular Breast Carcinoma
  Interventions:   Radiation: Radiation Therapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Radiation: Hypofractionated Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

  NCT03244384

  Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

  NCT03233711

  Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
  Interventions:   Biological: Nivolumab;   Other: Patient Observation
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

  NCT03087708

  Conditions:   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
  Interventions:   Drug: Naloxegol;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery

  NCT03033576

  Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
  Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

  NCT02927249

  Condition:   Node Positive HER2 Negative Breast Cancer
  Interventions:   Other: Placebo;   Drug: Aspirin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
  Recruiting
• Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes

  NCT02856581

  Condition:   Lung Carcinoma
  Interventions:   Drug: Varenicline;   Drug: Placebo;   Other: Tobacco Cessation Counseling
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Pfizer
  Recruiting
• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

  NCT02834013

  Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
  Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

  NCT02775851

  Condition:   Desmoplastic Melanoma
  Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826

  Condition:   Breast Carcinoma
  Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

  NCT02443077

  Conditions:   Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
  Interventions:   Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacogenomic Study;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992

  Conditions:   ALK Gene Rearrangement;   ALK Gene Translocation;   ALK Positive;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

  NCT02177695

  Condition:   Bladder Cancer
  Interventions:   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Methotrexate;   Drug: Vinblastine;   Drug: Doxorubicin;   Drug: Filgrastim
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

  NCT02003222

  Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

  NCT01896999

  Conditions:   Recurrent Classic Hodgkin Lymphoma;   Refractory Classic Hodgkin Lymphoma
  Interventions:   Drug: Brentuximab Vedotin;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• S0820, Adenoma and Second Primary Prevention Trial

  NCT01349881

  Condition:   Colorectal Neoplasms
  Interventions:   Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer Prevention Pharmaceuticals, Inc.
  Recruiting
• Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853

  Condition:   Lung Cancer
  Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

  NCT03395197

  Condition:   mCRPC
  Interventions:   Drug: Talazoparib with enzalutamide;   Drug: Placebo with enzalutamide
  Sponsors:   Pfizer;   Astellas Pharma Inc
  Recruiting
• Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

  NCT03375320

  Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Digestive System Neuroendocrine Neoplasm;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor;   Serotonin-Producing Pancreatic Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
  Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

  NCT02761057

  Conditions:   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Drug: Savolitinib;   Drug: Sunitinib;   Drug: Sunitinib Malate
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

  NCT02744092

  Conditions:   Cancer;   Venous Thromboembolism;   Deep Vein Thrombosis (DVT);   Pulmonary Embolism (PE);   Blood Clot
  Interventions:   Drug: Rivaroxaban;   Drug: Apixaban;   Drug: Edoxaban;   Drug: Dabigatran;   Drug: Warfarin;   Drug: Dalteparin;   Drug: Enoxaparin;   Drug: Fondaparinux
  Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute
  Recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer

  NCT02466971

  Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage IB2 Cervical Cancer AJCC v6 and v7;   Stage II Cervical Cancer AJCC v7;   Stage II Vaginal Cancer AJCC v6 and v7;   Stage IIA Cervical Cancer AJCC v7;   Stage IIB Cervical Cancer AJCC v6 and v7;   Stage III Vaginal Cancer AJCC v6 and v7;   Stage IIIB Cervical Cancer AJCC v6 and v7;   Stage IVA Cervical Cancer AJCC v6 and v7;   Stage IVA Vaginal Cancer AJCC v6 and v7;   Vaginal Adenocarcinoma;   Vaginal Adenosquamous Carcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
  Interventions:   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Drug: Triapine
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

  NCT01901094

  Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer
  Interventions:   Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

  NCT03204916

  Condition:   Acute Lymphoblastic Leukemia
  Interventions:   Other: Medical Chart Review;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Connect® MDS/AML Disease Registry

  NCT01688011

  Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia
  Intervention:  
  Sponsor:   Celgene
  Recruiting
• Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

  NCT00887146

  Condition:   Brain and Central Nervous System Tumors
  Interventions:   Drug: concomitant temozolomide (TMZ);   Radiation: radiotherapy;   Drug: procarbazine;   Drug: adjuvant temozolomide (TMZ);   Drug: CCNU;   Drug: vincristine
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   European Organisation for Research and Treatment Center (EORTC);   Canadian Cancer Trials Group
  Recruiting
• Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

  NCT00443274

  Condition:   Breast Implant
  Interventions:   Other: NBIR Placeholder;   Device: 410 Arm;   Device: BIFs
  Sponsor:   Allergan
  Recruiting
• Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

  NCT03500328

  Condition:   Multiple Sclerosis, Relapsing-Remitting
  Intervention:   Other: Early Aggressive Therapy or Traditional Therapy
  Sponsors:   Johns Hopkins University;   Patient-Centered Outcomes Research Institute
  Recruiting
• Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  NCT03150693

  Condition:   B Acute Lymphoblastic Leukemia
  Interventions:   Drug: Allopurinol;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Dexamethasone;   Drug: Pegylated L-Asparaginase;   Drug: Methotrexate;   Procedure: Bone Marrow Aspiration and Biopsy;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Biological: Rituximab;   Drug: Doxorubicin;   Drug: Thioguanine;   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors

  NCT03311334

  Conditions:   Neoplasms;   Melanoma;   Non Small Cell Lung Cancer (NSCLC);   Head and Neck Squamous Cell Carcinoma (HNSCC);   Renal Cell Carcinoma (RCC);   Urothelial Neoplasm;   Hepatocellular Carcinoma (HCC);   Microsatellite Instability-high or Mismatch Repair Deficient (MSI-H/dMMR);   Colorectal Cancer;   Gastroesophageal Junction Adenocarcinoma;   Gastric Cancer;   Cervical Cancer
  Interventions:   Drug: DSP-7888 Dosing Emulsion;   Drug: Nivolumab;   Drug: Pembrolizumab
  Sponsor:   Boston Biomedical, Inc
  Recruiting
• Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502

  NCT03609021

  Conditions:   Breast Carcinoma;   Estrogen Receptor Negative;   Progesterone Receptor Negative
  Interventions:   Procedure: Screening Mammography;   Procedure: Biospecimen Collection
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• A Study of Recombinant Vaccinia Virus in Combination With REGN2810 for Renal Cell Carcinoma

  NCT03294083

  Condition:   Renal Cell Carcinoma
  Interventions:   Biological: Pexastimogene Devacirepvec (Pexa-Vec);   Biological: REGN2810
  Sponsors:   SillaJen, Inc.;   Regeneron Pharmaceuticals
  Recruiting
• A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies

  NCT04014205

  Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma
  Intervention:   Drug: ICP-022
  Sponsor:   Beijing InnoCare Pharma Tech Co., Ltd.
  Recruiting
• Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

  NCT03448978

  Condition:   Multiple Myeloma
  Interventions:   Biological: Descartes-08;   Drug: Fludarabine;   Drug: Cyclophosphamide
  Sponsor:   Cartesian Therapeutics
  Recruiting
• Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

  NCT03976375

  Condition:   Metastatic Non-Small Cell Lung Cancer
  Interventions:   Biological: Pembrolizumab;   Drug: Lenvatinib;   Drug: Docetaxel
  Sponsors:   Merck Sharp & Dohme Corp.;   Eisai Inc.
  Recruiting
• Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer

  NCT03786081

  Condition:   Cervical Cancer
  Interventions:   Drug: Tisotumab Vedotin;   Drug: Bevacizumab;   Drug: Pembrolizumab;   Drug: Carboplatin
  Sponsors:   Genmab;   Seattle Genetics, Inc.;   European Network of Gynaecological Oncological Trial Groups (ENGOT);   Belgian Gynaecological Oncology Group;   Gynecologic Oncology Group;   Merck Sharp & Dohme Corp.
  Recruiting
• Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

  NCT02516813

  Condition:   Advanced Solid Tumors
  Interventions:   Drug: MSC2490484A;   Radiation: Fractionated RT;   Drug: Cisplatin
  Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
  Recruiting
• Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer

  NCT04095364

  Conditions:   Low Grade Ovarian Serous Adenocarcinoma;   Primary Peritoneal Low Grade Serous Adenocarcinoma;   Stage II Ovarian Cancer AJCC v8;   Stage IIA Ovarian Cancer AJCC v8;   Stage IIB Ovarian Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   TP53 Negative
  Interventions:   Drug: Carboplatin;   Drug: Letrozole;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Guiding Treatment for Patients With Brain Metastases

  NCT03994796

  Conditions:   CDK Gene Mutation;   Metastatic Malignant Neoplasm in the Brain;   Metastatic Malignant Solid Neoplasm;   NTRK Family Gene Mutation;   PI3K Gene Mutation;   ROS1 Gene Mutation
  Interventions:   Drug: Abemaciclib;   Drug: PI3K Inhibitor GDC-0084;   Drug: Entrectinib
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Genentech, Inc.
  Recruiting
• A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

  NCT03976362

  Condition:   Carcinoma, Squamous Cell, Non-small-cell Lung
  Interventions:   Biological: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Nab-paclitaxel;   Drug: Olaparib;   Drug: Placebo
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

  NCT03976323

  Condition:   Carcinoma, Non-squamous Non-small-cell Lung
  Interventions:   Biological: Pembrolizumab;   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Olaparib
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

  NCT03944941

  Conditions:   Skin Squamous Cell Carcinoma;   Metastatic Skin Cancer
  Interventions:   Drug: Avelumab;   Drug: Cetuximab
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

  NCT03937635

  Condition:   Smoldering Plasma Cell Myeloma
  Interventions:   Biological: Daratumumab;   Drug: Dexamethasone;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

  NCT03893682

  Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Non-Hodgkin's Lymphoma
  Intervention:   Drug: CG-806
  Sponsor:   Aptose Biosciences Inc.
  Recruiting
• Tenofovir Alafenamide in Preventing Liver Complications in Participants With Current or Past Hepatitis B Virus Who Are Receiving Anti-Cancer Therapy for Solid Tumors

  NCT03887702

  Conditions:   Hepatitis B Virus Positive;   Malignant Solid Neoplasm
  Interventions:   Other: Best Practice;   Other: Laboratory Biomarker Analysis;   Drug: Tenofovir Alafenamide
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382

  Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

  NCT03851445

  Condition:   Previously Treated Non-Small Cell Lung Cancer
  Intervention:   Drug: Screening Platform
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

  NCT03839940

  Condition:   Malignant Neoplasm
  Interventions:   Drug: Dexamethasone;   Other: Placebo;   Other: Questionnaire;   Other: Quality-of-Life Assessment;   Drug: Everolimus
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

  NCT03834519

  Condition:   Prostatic Neoplasms
  Interventions:   Biological: Pembrolizumab;   Drug: Olaparib;   Drug: Abiraterone acetate;   Drug: Prednisone;   Drug: Enzalutamide
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

  NCT03834506

  Condition:   Prostatic Neoplasms
  Interventions:   Biological: Pembrolizumab;   Drug: Docetaxel;   Drug: Prednisone;   Drug: Placebo;   Drug: Dexamethasone
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

  NCT03834493

  Condition:   Prostatic Neoplasms
  Interventions:   Biological: Pembrolizumab;   Drug: Enzalutamide;   Drug: Placebo
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer (NSCLC)(MK-7902-007/E7080-G000-314/LEAP-007)

  NCT03829332

  Condition:   Non-small Cell Lung Cancer
  Interventions:   Biological: Pembrolizumab;   Drug: Lenvatinib;   Drug: Placebo for lenvatinib
  Sponsors:   Merck Sharp & Dohme Corp.;   Eisai Inc.
  Recruiting
• Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

  NCT03820986

  Condition:   Malignant Melanoma
  Interventions:   Biological: Pembrolizumab;   Drug: Lenvatinib;   Drug: Placebo for lenvatinib
  Sponsors:   Merck Sharp & Dohme Corp.;   Eisai Inc.
  Recruiting
• Testing Maintenance Immunotherapy Versus Observation in Patients With Oropharynx Cancer

  NCT03811015

  Conditions:   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Nivolumab;   Other: Patient Observation
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer

  NCT03785925

  Conditions:   Urinary Bladder Neoplasm;   Neoplasm Metastasis
  Interventions:   Biological: Bempegaldesleukin;   Biological: Nivolumab
  Sponsors:   Nektar Therapeutics;   Bristol-Myers Squibb
  Recruiting
• Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414

  Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
  Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making

  NCT03766009

  Conditions:   Breast Cancer Stage 0;   Breast Cancer Stage I;   Breast Cancer Stage II;   Breast Cancer Stage III
  Interventions:   Other: Usual Care;   Other: Web-based decision aid
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Agency for Healthcare Research and Quality (AHRQ)
  Recruiting
• Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

  NCT03765918

  Condition:   Head and Neck Neoplasms
  Interventions:   Biological: Pembrolizumab 200 mg;   Radiation: Radiotherapy 60 Gray/day;   Radiation: Radiotherapy 66 Gray/day;   Radiation: Radiotherapy 70 Gray/day;   Drug: Cisplatin 100 mg/m^2
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer

  NCT03750786

  Condition:   Colo-rectal Cancer
  Interventions:   Drug: Arfolitixorin;   Drug: Leucovorin
  Sponsor:   Isofol Medical AB
  Recruiting
• Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)

  NCT03737994

  Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Interventions:   Drug: Alectinib;   Drug: Brigatinib;   Drug: Carboplatin;   Drug: Ceritinib;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Ensartinib;   Drug: Lorlatinib;   Drug: Pemetrexed
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD

  NCT03729362

  Condition:   Pompe Disease (Late-onset)
  Interventions:   Drug: AT2221;   Biological: alglucosidase alfa;   Biological: ATB200
  Sponsor:   Amicus Therapeutics
  Recruiting
• Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

  NCT03725059

  Condition:   Breast Cancer
  Interventions:   Biological: Pembrolizumab (K);   Drug: Placebo (P);   Drug: Paclitaxel (X);   Drug: Doxorubicin hydrochloride (A);   Drug: Epirubicin (E);   Drug: Cyclophosphamide (C);   Drug: Endocrine therapy;   Radiation: Radiation therapy;   Procedure: Surgery
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT03717012

  Condition:   Idiopathic Pulmonary Fibrosis
  Interventions:   Drug: Nintedanib;   Other: Pulmonary rehabilitation program
  Sponsor:   Boehringer Ingelheim
  Recruiting
• Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer

  NCT03712605

  Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
  Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

  NCT03703297

  Condition:   Small Cell Lung Cancer
  Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Other: Placebo
  Sponsor:   AstraZeneca
  Recruiting
• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

  NCT03701334

  Condition:   Early Breast Cancer
  Interventions:   Drug: Ribociclib;   Other: Endocrine Therapy
  Sponsors:   Novartis Pharmaceuticals;   Translational Research in Oncology
  Recruiting
• Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

  NCT03701308

  Condition:   Acute Myeloid Leukemia
  Interventions:   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Uproleselan
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

  NCT03694002

  Conditions:   Locally Advanced Thymic Carcinoma;   Metastatic Thymic Carcinoma;   Recurrent Thymic Carcinoma;   Unresectable Thymic Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Ramucirumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114

  Condition:   Relapsing Multiple Sclerosis
  Interventions:   Biological: Ofatumumab;   Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap);   Biological: 13-valent pneumococcal conjugate vaccine (13-PCV);   Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV);   Biological: Seasonal Quadrivalent influenza vaccine;   Biological: Keyhole limpet hemocyanin (KLH) neo-antigen
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Dose Dense Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

  NCT03609216

  Conditions:   Infiltrating Bladder Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma;   Stage III Bladder Urothelial Carcinoma
  Interventions:   Drug: Gemcitabine Hydrochloride;   Drug: Cisplatin;   Biological: Pegfilgrastim;   Procedure: Conventional Surgery;   Procedure: Radical Cystectomy;   Other: Chemoradiotherapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

  NCT03539536

  Condition:   Non-small Cell Lung Cancer
  Intervention:   Drug: Telisotuzumab vedotin
  Sponsor:   AbbVie
  Recruiting
• QUILT 2.023: A Study of N803 in Combination With Pembrolizumab vs Pembrolizumab Alone as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

  NCT03520686

  Condition:   Non Small Cell Lung Cancer
  Interventions:   Drug: N-803 + Pembrolizumab;   Drug: Pembrolizumab
  Sponsors:   Altor BioScience;   NantCell, Inc.
  Recruiting
• A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

  NCT03498716

  Condition:   Triple Negative Breast Cancer
  Interventions:   Drug: Atezolizumab;   Drug: Paclitaxel;   Drug: Dose-dense Doxorubicin or dose-dense Epirubicin;   Drug: Cyclophosphamide
  Sponsors:   Hoffmann-La Roche;   Breast International Group;   Alliance Foundation Trials (AFT);   Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU);   Frontier Science and Technology Research Foundation Inc (FS)
  Recruiting
• A Study of Atezolizumab (Anti−Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  NCT03452137

  Condition:   Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  Interventions:   Drug: Atezolizumab;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

  NCT03425643

  Condition:   Non-small Cell Lung Cancer
  Interventions:   Biological: Pembrolizumab;   Drug: Placebo;   Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Pemetrexed
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

  NCT03418961

  Conditions:   Cardiotoxicity;   HER2/Neu Positive;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Patient Observation
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

  NCT03412565

  Condition:   Multiple Myeloma
  Interventions:   Drug: Daratumumab;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Prednisone;   Drug: Carfilzomib
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)

  NCT03398655

  Condition:   Recurrent Platinum Resistant Ovarian Cancer
  Interventions:   Drug: VB-111 + Paclitaxel;   Drug: Placebo + Paclitaxel
  Sponsors:   Vascular Biogenics Ltd. operating as VBL Therapeutics;   GOG Foundation, Inc.
  Recruiting
• Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION 2)

  NCT03393884

  Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
  Interventions:   Biological: GEN-1;   Drug: Carboplatin;   Drug: Paclitaxel
  Sponsor:   Celsion
  Recruiting
• BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER

  NCT03371719

  Conditions:   PSA Progression;   Stage III Prostate Adenocarcinoma;   Stage IV Prostate Adenocarcinoma
  Interventions:   Drug: Apalutamide;   Radiation: External Beam Radiation Therapy;   Other: Placebo
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

  NCT03326674

  Condition:   Breast Cancer
  Interventions:   Drug: Tesetaxel and Capecitabine;   Drug: Capecitabine
  Sponsor:   Odonate Therapeutics, Inc.
  Recruiting
• Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer

  NCT03304639

  Conditions:   Stage III Merkel Cell Carcinoma AJCC v7;   Stage IIIA Merkel Cell Carcinoma AJCC v7;   Stage IIIB Merkel Cell Carcinoma AJCC v7;   Stage IV Merkel Cell Carcinoma AJCC v7
  Interventions:   Biological: Pembrolizumab;   Radiation: Stereotactic Body Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

  NCT03269669

  Conditions:   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Recurrent Follicular Lymphoma;   Refractory Follicular Lymphoma
  Interventions:   Drug: Bendamustine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Lenalidomide;   Biological: Obinutuzumab;   Drug: Prednisone;   Drug: Umbralisib;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Strategic Management to Improve CRT Using Multi-Site Pacing Post Approval Study (Reference # C1918)

  NCT03257436

  Condition:   Left Ventricular Dysfunction
  Intervention:   Device: CRT-D
  Sponsors:   Boston Scientific Corporation;   ICON Clinical Research
  Recruiting
• Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

  NCT03251092

  Conditions:   Healthy Volunteer - Complete;   Cystic Fibrosis
  Interventions:   Drug: PTI-808;   Drug: Placebo;   Drug: PTI-428;   Drug: PTI-801
  Sponsor:   Proteostasis Therapeutics, Inc.
  Recruiting
• Electronic Patient Reporting of Symptoms During Cancer Treatment

  NCT03249090

  Conditions:   Advanced Cancer;   Metastatic Cancer
  Interventions:   Other: Patient Self-Reporting of Symptoms;   Other: Usual Care Delivery
  Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute;   University of North Carolina;   Mayo Clinic;   American Society of Clinical Oncology;   American Cancer Society, Inc.;   Dana-Farber Cancer Institute
  Recruiting
• QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer

  NCT03228667

  Conditions:   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Urothelial Carcinoma;   Head and Neck Squamous Cell Carcinoma;   Merkel Cell Carcinoma;   Melanoma;   Renal Cell Carcinoma;   Gastric Cancer;   Cervical Cancer;   Hepatocellular Carcinoma;   Microsatellite Instability;   Mismatch Repair Deficiency;   Colorectal Cancer
  Interventions:   Drug: ALT-803 + Pembrolizumab;   Drug: ALT-803 + Nivolumab;   Drug: ALT-803 + Atezolizumab;   Drug: ALT-803 + Avelumab
  Sponsor:   Altor BioScience
  Recruiting
• Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

  NCT03228537

  Conditions:   Biphasic Mesothelioma;   Epithelioid Mesothelioma;   Stage I Pleural Malignant Mesothelioma AJCC v7;   Stage IA Pleural Malignant Mesothelioma AJCC v7;   Stage IB Pleural Malignant Mesothelioma AJCC v7;   Stage II Pleural Malignant Mesothelioma AJCC v7;   Stage III Pleural Malignant Mesothelioma AJCC v7
  Interventions:   Drug: Atezolizumab;   Drug: Cisplatin;   Procedure: Extrapleural Pneumonectomy;   Drug: Pemetrexed Disodium;   Procedure: Pleurectomy;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

  NCT03224767

  Conditions:   BRAF V600E Mutation Present;   Papillary Craniopharyngioma
  Interventions:   Drug: Vemurafenib;   Drug: Cobimetinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

  NCT03180294

  Conditions:   Breast Carcinoma;   Cervical Carcinoma;   Ovarian Carcinoma;   Postmenopausal;   Uterine Corpus Cancer;   Vaginal Carcinoma;   Vulvar Carcinoma
  Interventions:   Drug: Bupropion Hydrochloride;   Other: Placebo
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6)

  NCT03173092

  Condition:   Multiple Myeloma
  Interventions:   Drug: Ixazomib;   Drug: Lenalidomide;   Drug: Dexamethasone
  Sponsor:   Millennium Pharmaceuticals, Inc.
  Recruiting
• An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

  NCT03084471

  Condition:   Advanced Solid Malignancies
  Interventions:   Biological: MEDI4736 (Durvalumab);   Biological: MEDI4736 (Durvalumab) + Tremelimumab
  Sponsor:   AstraZeneca
  Recruiting
• Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

  NCT03070886

  Conditions:   Stage I Prostate Adenocarcinoma;   Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
  Interventions:   Drug: Bicalutamide;   Drug: Docetaxel;   Radiation: External Beam Radiation Therapy;   Drug: Flutamide;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Drug: Leuprolide Acetate;   Drug: Nilutamide
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

  NCT03057951

  Condition:   Heart Failure
  Interventions:   Drug: Empagliflozin;   Drug: Placebo
  Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
  Recruiting
• Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

  NCT03056755

  Condition:   Breast Cancer
  Interventions:   Drug: alpelisib;   Drug: fulvestrant;   Drug: letrozole;   Drug: Goserelin;   Drug: Leuprolide
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

  NCT02998528

  Condition:   Non Small Cell Lung Cancer
  Interventions:   Biological: Nivolumab;   Drug: Cisplatin;   Drug: Vinorelbine;   Drug: Gemcitabine;   Drug: Docetaxel;   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Ipilimumab
  Sponsors:   Bristol-Myers Squibb;   Ono Pharmaceutical Co. Ltd
  Recruiting
• Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

  NCT02997228

  Conditions:   Colorectal Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

  NCT02954874

  Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

  NCT02928497

  Condition:   Stroke
  Interventions:   Device: WATCHMAN LAAC Device Implant;   Drug: Single Antiplatelet Therapy or No Therapy (Control)
  Sponsor:   Boston Scientific Corporation
  Recruiting
• Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS

  NCT02926911

  Conditions:   DCIS;   Ductal Carcinoma in Situ
  Interventions:   Other: Guideline Concordant Care;   Other: Active Surveillance
  Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute;   Duke University;   Dana-Farber Cancer Institute;   M.D. Anderson Cancer Center;   New York University;   Washington University School of Medicine
  Recruiting
• Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

  NCT02924376

  Condition:   Cholangiocarcinoma
  Intervention:   Drug: Pemigatinib
  Sponsor:   Incyte Corporation
  Recruiting
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  NCT02912559

  Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

  NCT02793583

  Conditions:   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
  Interventions:   Drug: TGR-1202 + Ublituximab;   Drug: TGR-1202;   Drug: TGR-1202 + Ublituximab + Bendamustine
  Sponsor:   TG Therapeutics, Inc.
  Recruiting
• Standardized Treatment of Pulmonary Exacerbations II

  NCT02781610

  Condition:   Pulmonary Cystic Fibrosis
  Intervention:   Drug: Standard of care IV antibiotic(s)
  Sponsors:   Chris Goss;   Cystic Fibrosis Foundation;   CF Therapeutics Development Network Coordinating Center;   Medical University of South Carolina;   University of Washington
  Recruiting
• S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

  NCT02728596

  Conditions:   Febrile Neutropenia;   Stage 0 Breast Cancer;   Stage 0 Colorectal Cancer;   Stage 0 Non-Small Cell Lung Cancer;   Stage I Colorectal Cancer;   Stage IA Breast Cancer;   Stage IA Non-Small Cell Lung Carcinoma;   Stage IB Breast Cancer;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Breast Cancer;   Stage IIA Colorectal Cancer;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Breast Cancer;   Stage IIB Colorectal Cancer;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIC Colorectal Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Colorectal Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colorectal Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colorectal Cancer;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
  Interventions:   Other: Preventive Intervention;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Patient-Centered Outcomes Research Institute
  Recruiting
• Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer

  NCT02635009

  Conditions:   Extensive Stage Small Cell Lung Carcinoma;   Limited Stage Small Cell Lung Carcinoma
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Other: Cognitive Assessment;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
  Recruiting
• Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02502266

  Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Questionnaire Administration;   Drug: Topotecan;   Drug: Topotecan Hydrochloride
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

  NCT02224781

  Conditions:   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
  Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

  NCT02179086

  Conditions:   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
  Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: photon beam radiation therapy;   Radiation: proton beam radiation therapy;   Drug: temozolomide;   Other: laboratory biomarker analysis
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
  Recruiting
• Dimethyl Fumarate (DMF) Observational Study

  NCT02047097

  Condition:   Multiple Sclerosis
  Intervention:   Drug: dimethyl fumarate
  Sponsor:   Biogen
  Recruiting
• Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

  NCT02004275

  Condition:   Multiple Myeloma in Relapse
  Interventions:   Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Celgene Corporation;   Millennium Pharmaceuticals, Inc.
  Recruiting
• Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

  NCT01872975

  Conditions:   Stage IB Breast Cancer;   Stage II Breast Cancer
  Interventions:   Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
  Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
  Recruiting
• Multi-Institutional Registry for Prostate Cancer Radiosurgery

  NCT01226004

  Conditions:   Prostate Cancer Early Risk Treated by Radiosurgery;   Prostate Cancer Intermediate Risk Treated by Radiosurgery
  Intervention:  
  Sponsor:   Florida Robotic Radiosurgery Association
  Recruiting
• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

  NCT03907488

  Conditions:   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IIIA Hodgkin Lymphoma;   Ann Arbor Stage IIIB Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IVA Hodgkin Lymphoma;   Ann Arbor Stage IVB Hodgkin Lymphoma;   Classic Hodgkin Lymphoma;   Lymphocyte-Rich Classic Hodgkin Lymphoma
  Interventions:   Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Biological: Filgrastim;   Biological: Nivolumab;   Biological: Pegfilgrastim;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Vinblastine;   Drug: Vinblastine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296

  Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Intervention:   Drug: Rucaparib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting